Seeing Is Believing
Currently out of the existing stock ratings of Jami Rubin, 39 are a BUY (60.94%), 17 are a HOLD (26.56%), 8 are a SELL (12.5%).
Analyst Jami Rubin works with a stock forecast success ratio of 84.62% fulfilled within 486.31 days on average. Previously, Jami Rubin worked at GOLDMAN SACHS.
Jami Rubin’s has documented 143 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 01-Oct-2018.
Analyst best performing recommendations are on ALNY (ALNYLAM PHARMACEUTICALS).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 11/6/2017. The price target of $13 was fulfilled within 11 days with a profit of $0.67 (5.43%) receiving and performance score of 4.94.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
195
$27.2 (16.21%)
185
1 months 2 days ago
10/12 (83.33%)
$14.65 (8.12%)
191
Buy
189
$21.2 (12.63%)
181
2 months 23 days ago
9/11 (81.82%)
$15.71 (9.07%)
252
Buy
195
$27.2 (16.21%)
180
2 months 23 days ago
9/10 (90%)
$21.71 (12.53%)
445
Hold
165
$-2.8 (-1.67%)
157
3 months 12 days ago
11/11 (100%)
$2.96 (1.83%)
314
Buy
180
$12.2 (7.27%)
195
3 months 26 days ago
3/5 (60%)
$21.06 (13.25%)
496
What Year was the first public recommendation made by Jami Rubin?